Idera Pharmaceuticals Inc. (IDRA)
Symbol Info
Listed Symbol IDRA
Name Idera Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $662,000
Latest Fiscal EPS $-2.27
Price Info
21 Day Moving Average $2.7500
21 Day EMA $2.661380
50 Day Moving Average $2.5968
50 Day EMA $2.657850
200 Day EMA $3.654370
200 Day Moving Average 2.739350
52 Week High $9.55
52 Week Low $2.08
52 Week Change $-67.792200
Alpha -0.019818
Beta 2.3732
Standard Deviation 0.249917
R2 0.106458
Periods 60
Share Information
10 Day Average Volume 153,635
20 Day Average Volume 130,534
30 Day Average Volume 189,027
50 Day Average Volume 168,524
Outstanding Shares 28,843,528
Float Shares 27,406,241
Percent Float 95.02%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 159
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 1,214,921
Institute Holdings Percent 41.700000
Institute Sold Previous 3 Months 2,564,452
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 17
Insider Holdings Percent 5.00%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,437,287
Price Change
7 Day Price Change $-0.27
7 Day Percent Change -9.82%
21 Day Price Change $-0.3199999
21 Day Percent Change -11.43%
30 Day Price Change $-0.6399999
30 Day Percent Change -20.51%
Month To Date Price Change $-0.41
Month To Date Percent -14.19%
90 Day Price Change $-0.05
90 Day Percent Change -1.98%
Quarter To Date $-0.41
Quarter To Date Percent -14.19%
180 Day Price Change $-0.33
180 Day Percent Change -11.74%
200 Day Price Change $-0.13
200 Day Percent Change -4.98%
Year To Date $-0.29
Year To Date Percent -10.47%
Profile
Description Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. The company has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates. The 3GA technology is used to create drug candidates to turn off the RNA messengers associated with genes causing various diseases.
Details
Issue Type CS
Market Cap $71,531,949
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 28,843,528
CEO Vincent J. Milano
Employees 36
Last Audit UQ
Classification
CIK 0000861838
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 505 Eagleview Boulevard
Suite 212
Exton, PA 19341
Website https://www.iderapharma.com
Facisimile
Telephone +1 484 348-1600
Email rdoody@iderapharma.com
Key Ratios
Profitability
EBIT Margin -2,713.1
EBITDA Margin -2,702.5
Pre-Tax Profit Margin -17,806.4
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $1,547,000
Revenue Per Share $0.0536
Revenue 3 Years $-37.95
Revenue 5 Years $71.39
Valuation Measures
PE Ratio -
Enterprise Value $31,173,795
Price To Sales 46.239140
Price To Free Cash -2.2
PE High Last 5 Years -
Price To Book 1.6
Price To Cash Flow 6.0
PE Low Last 5 Years -
Price To Tangible Book 1.6
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 8.2
Leverage Ratio 1.1
Quick Ratio 8.0
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -59.68
Return On Equity -69.13
Return On Capital -70.96
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
IDRA
Idera Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191016 19:36:09